How are energy investors positioned?
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel – Lifeward Ltd. (NASDAQ: LFWD), a pioneer in medical technology for individuals with physical disabilities, has announced the national launch of the ReWalk 7 Personal Exoskeleton in the United States. This latest generation device is designed to aid individuals with spinal cord injury (SCI) by providing a more personalized and functional walking experience with new features such as cloud connectivity and customizable walking speeds. According to InvestingPro data, the company has demonstrated impressive revenue growth of 85% over the last twelve months, though its stock currently trades at an attractive price-to-book ratio of 0.81, suggesting potential undervaluation.
The ReWalk 7, which obtained FDA clearance in March 2025, is the result of several years of development, incorporating advanced technology and user feedback. Larry Jasinski, CEO of Lifeward, highlighted the device’s optimization for real-world use and the enhanced freedom of movement it offers to users. The company’s collaboration with end users and physical therapists during the FDA clearance process was key in refining the product for practical applications. InvestingPro analysis reveals the company maintains a healthy balance sheet with more cash than debt and a current ratio of 2.08, providing financial flexibility to support its product development initiatives.
Key advancements of the ReWalk 7 include smoother movement with two customizable walking speeds for different environments, more control with a new Crutch Control feature, smarter walking through a Wrist Control smartwatch and the MyReWalk mobile app, increased accessibility with an improved battery, and better training tools for therapists.
The ReWalk 7’s launch follows significant developments for the product line, including a 2023 update that allowed users to navigate stairs and curbs, and a 2024 decision by the Centers for Medicare & Medicaid Services (CMS) to establish a Medicare reimbursement pathway for personal exoskeletons, broadening the device’s accessibility to more SCI patients.
Lifeward, founded in 2001 with operations in the United States, Israel, and Germany, is committed to creating life-changing solutions for people with physical limitations or disabilities. The company’s portfolio includes the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the ReStore Exo-Suit, and the MyoCycle FES System.
This announcement is based on a press release statement from Lifeward Ltd. The ReWalk 7 is now available for purchase in the U.S. for personal and clinical use. For further details, interested parties are directed to Lifeward’s website. Investors seeking deeper insights into Lifeward’s financial health and growth prospects can access comprehensive analysis through InvestingPro, which offers exclusive access to 13 additional ProTips and detailed financial metrics, including analyst price targets ranging from $3 to $13 per share.
In other recent news, Lifeward Ltd. reported its preliminary financial results for the first quarter of 2025, with revenues around $5 million and operating expenses anticipated between $6.5 million and $6.7 million. These figures are preliminary and unaudited, with a full quarterly report expected later. The company also announced the FDA’s clearance of its ReWalk 7 exoskeleton, a significant development in assistive technology for individuals with spinal cord injuries. Meanwhile, H.C. Wainwright reaffirmed its Buy rating and $13 price target for Lifeward, expressing confidence in the company’s growth prospects. Despite these positive developments, Lifeward’s fourth-quarter 2024 earnings fell short of expectations, with a reported revenue of $7.5 million against a forecast of $10.3 million. The company’s Chief Sales Officer, Charles Remsberg, will depart at the end of May 2025, a move classified as a termination without cause. Lifeward aims to enhance its market reach and has outlined a strategy for 2025, focusing on sustainable growth and expense reduction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.